spg302
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 3, 2023 (NCT05882695)
Timeline
Indications
Mechanism of action
- Actin, cytoplasmic 1INHIBITOR
ACTB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06903286 | Phase 2 | May 29, 2025 | Spinogenix |
| NCT06833281 | Phase 2 | Mar 1, 2025 | Flinders University, Spinogenix, University of New South Wales |
| NCT06442462 | Phase 2 | Aug 1, 2024 | Monash University, Spinogenix |
| NCT06427668 | Phase 2 | Jul 29, 2024 | Flinders University, Spinogenix, University of New South Wales |
| NCT05882695 | Phase 1 | Jul 3, 2023 | Novotech, Nucleus Network Ltd, Spinogenix |
| NCT07088159 | N/A | — | Spinogenix |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spinogenix | For profit | 6 | 6 | 3 | 2023 |
| Flinders University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| University of New South Wales | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Novotech | For profit | 1 | 0 | 1 | 2023 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1